Is RVTY a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on RVTY is $145.00, +16.2% from the $124.75 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $100.00, -19.8% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Revvity is worth if the risks below bite instead of the drivers above.

The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, the stock sits at the top of its 52-week range, which leaves little room for a guidance miss.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RVTY already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

15 analysts cover RVTY, with an average target of $121.07 (-2.9% against $124.75) and a split of 6 buy, 11 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RVTY forecast and price target page.

• Revenue (TTM): ~$2.912 billion for the twelve months to July 5, 2026, derived from ~$2.856 billion in fiscal 2025 plus first-half 2026 revenue of ~$1.441 billion less first-half 2025 revenue of ~$1.385 billion. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. June-quarter revenue was ~$729.7 million versus ~$720.3 million. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025.
• GAAP earnings versus adjusted earnings: Trailing twelve-month net income is ~$237.6 million and trailing diluted EPS ~$2.08, down from $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS from continuing operations was $1.41 in the June quarter against $1.18, and $2.47 for the half against $2.19. The bridge for the quarter is $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Full-year 2026 pro forma adjusted EPS is guided to $5.30 to $5.40, raised on August 4, 2026 from $5.20 to $5.30.
• Segment and product-line mix: First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%). Consolidated adjusted operating income was ~$211.0 million at a 28.9% margin, against GAAP operating income of ~$89.3 million at 12.2%. Corporate cost was ~$13.4 million in the quarter.
• Cash flow and balance sheet: Operating cash flow from continuing operations was ~$317.8 million in the first half of 2026 versus ~$268.4 million a year earlier, on capital expenditure of ~$30.8 million, and was ~$589.0 million for full-year 2025. Cash stood at ~$1.023 billion on July 5, 2026 against ~$3.222 billion of debt principal, of which the EUR 500.0 million 1.875% notes were repaid at maturity in July for ~$571.2 million. That leaves ~$2.65 billion outstanding across notes maturing 2028, 2029, two 2031 tranches and 2051, plus an undrawn $1.5 billion revolver running to January 2030. Goodwill is ~$6.61 billion, net intangibles ~$2.22 billion, equity ~$7.23 billion.
• Market pricing: The shares closed at ~$124.75 on August 21, 2026 against a 52-week range of ~$81.22 to ~$124.97, giving a market capitalization of ~$13.9 billion on ~111.6 million shares outstanding as of July 5, 2026. There is one class of common stock, with 300 million authorized. Trailing GAAP P/E is ~60x; against the midpoint of 2026 adjusted EPS guidance the multiple is ~23x. Price-to-sales is ~4.8x on trailing revenue. Enterprise value is ~$16.1 billion after netting ~$2.2 billion of net debt, which puts EV/sales near 5.5x and EV/adjusted EBITDA in the high teens against roughly $890 million of implied 2026 adjusted EBITDA.
• Dividend and buyback: The quarterly dividend is $0.07 a share, $0.28 annualized, for a yield of roughly 0.2% at the current price. Repurchases do the heavy lifting instead: ~$820.8 million in fiscal 2025 and ~$102.5 million in the first half of 2026, cutting weighted average diluted shares to ~111.7 million from ~118.9 million year over year. Research and development spending was ~$106.9 million in the half, flat against the prior year and about 7.4% of revenue.

The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 60x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a forward multiple near 23x on guided adjusted EPS treats that amortization as sunk. Either way the stock is priced above the mid-teens multiples common in slow-growth diagnostics and below the premium attached to faster-compounding life-science tools names. Revenue growth of 4% to 5% organic, with margin and buyback doing the rest, is what the current price appears to assume.

Rather than asking whether RVTY is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold RVTY indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: the most immediate risk is that a chunk of 2026 profit does not repeat fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RVTY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RVTY against your real portfolio and see your actual exposure before deciding.